In 2021 the European Haemophilia Consortium (EHC) received funding from the sources below. The accounts of the EHC are audited by an external auditor and approved by its members during its Annual General Assembly.

The full accounts can be consulted in the EHC 2021 Annual Report.

 


EHC Funding 2021 - Industry versus non-industry funding

Source of incomeAmount in €% of the total income
Non-industry288,643.2913%
Industry1,850,00087%
Highest industry contribution285,00013%

EHC non-industry funding - 2021

Funding source Amount in €% of the total income
EHC membership11,1500.5%
Volunteer (non-remunerated) contributions267,00012%
Other sources of support1,840.450.08%
Other operating income1,137.960.05%
EHC Conference surplus7,514.880.3%
Subtotal288,643.2913%

EHC industry-related funding - 2021

Funding sourceAmount in €% of total income
Bayer105,0004.9%
BioMarin237,00011.1%
Biotest10,0000.46%
CSL Behring85,0003.9%
Freeline5,0000.23%
Kedrion15,0000.23%
LFB10,0000.46%
Novo Nordisk95,0004,4%
Pfizer90,0004.2%
Roche285,00013,3%
Sanofi275,00012.8%
Sigilon5,0000.23%
Sobi265,00012.4%
Spark130,0006%
Takeda235,00010.9%
UniQure3,0000.14%
Vifor10,0000.46%
Subtotal1,850,00087%